Corporate Governance
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane® which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.
| Document | View | ||
|---|---|---|---|
| Code of Business Conduct and Ethics |
51.0 KB
|
||
| Corporate Governance Guidlines |
59.3 KB
|
||
| Audit Committee Charter |
51.3 KB
|
||
| Compensation Committee Charter |
34.9 KB
|
||
| Nominating and Corporate Governance Committee Charter |
36.2 KB
|
||
| Science and Technology Committee Charter |
29.7 KB
|
||
